Real-world outcomes of mosunetuzumab use in relapsed/refractory indolent lymphomas: a CUBIC consortium analysis.
Mosunetuzumab (mosun) is a CD20 × CD3 bispecific antibody approved for follicular lymphoma. Most cases of cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome were low grade, with no differences in survival between trial-eligible and trial-ineligible patients.
Mosunetuzumab (mosun) is a CD20 × CD3 bispecific antibody approved for follicular lymphoma. Most cases of cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome were low grade, with no differences in survival between trial-eligible and trial-ineligible patients.
What the study was
- Study design
- Retrospective observational study
- Population
- Human participants; details are provided in the abstract.
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Blood neoplasia
Why it surfaced
Retained as a 8/10 high-priority candidate for Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma); PubMed metadata and abstract were assessed conservatively.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.